author-photo

Bo Chao

Takeda Pharmaceutical Company

2

Papers

0

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)